Meetings

Friday Satellite Symposia

The 2021 Friday Satellite Symposia (FSS) program concluded on December 10. If on demand content is made available to ASH it will be posted here. Questions regarding 2021 FSS programs should be directed to the managing company contacts listed below each session. 

The application for the 2022 program will be available in March. ASH is excited to share upcoming FSS program details soon.

ASH appreciates its corporate and nonprofit partners for their participation in FSS. The Society values its partnerships and the supportive role that members of this community play in an effort to provide hematologists with quality educational programs. Please review the official FSS guidelines to learn about hosting a symposium. For reference, ASH submission materials can be found on the application site.

For more information, contact Kelly Cade, Grants and Satellite Symposia Manager, Consultant, at fss@hematology.org.


  • 1

    Morning Symposia

    7:00 a.m. - 10:00 a.m.
    Eastern time

    A Better Blend for Follicular Lymphoma: How Targeted, Epigenetic, and Immune Therapies Are Changing Patient Care

    This program is supported by educational grants from Epizyme, Inc.; MEI Pharma, Inc.; and TG Therapeutics.


    7:00 a.m. - 10:00 a.m. Eastern time
    VIRTUAL PROGRAM

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    PeerView’s unique CME-certified virtual ‘Clinical Consults’ symposium will guide learners through the modern realities of managing R/R FL, where a better blend of therapeutics can be selected and sequenced to provide maximum benefit for patients. Our expert panel will discuss cases that will be directly linked to mini-lectures, providing the evidence that supports the continued integration of novel antibodies, targeted and epigenetic agents, and CAR-T therapies into patient management. The experts will also discuss the foundational science that underlies the use of these agents in order to achieve the goal of improving patient outcomes in R/R FL. Register today for this informative and practical live virtual symposium!

    Chair:

    Nathan H. Fowler, MD
    The University of Texas MD Anderson Cancer Center
    Houston, TX

    Speakers:

    Nancy L. Bartlett, MD
    Washington University Sch. of Med. Siteman Cancer Center
    Saint Louis, MO

    Krish Patel, MD
    Swedish Cancer Institute, Center for Blood Disorders and Stem Cell Transplantation
    Seattle, WA

    Margaret Walker , PVI, PeerView Institute for Medical Education
    Email: margaret.walker@peerview.com

    ACCESS PROGRAM HERE


    A Glimpse Into the Future of Myeloma Patient Management

    This program is supported by the Multiple Myeloma Research Foundation with funding provided by AbbVie, Amgen, Bristol Myers Squibb, Karyopharm Therapeutics, Oncopeptides, and Sanofi Genzyme.


    7:00 a.m. - 10:00 a.m. Eastern time
    Georgia World Congress Center
    Thomas Murphy Ballroom 1-2, Level 5

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    In the last 18 years, oncology clinicians and patients have witnessed significant advances in multiple myeloma (MM) management, with the development of new strategies for establishing diagnosis, assessing prognosis, monitoring minimal residual disease, and delivering supportive care. In this time, 16 new drugs have been approved by the US Food and Drug Administration (FDA) for use in MM—including ten new MM approved in the last 6 years alone. The rapidity with which clinical data relating to MM therapy (including the MM precursor condition smoldering multiple myeloma) continues to evolve and emerge all but ensures that the treatment paradigm will continue to change significantly in the future.

    To help hematologist-oncologists prepare for how patient management may change, this symposium will feature four topics and speakers will present a review of how patient management is approached today or how it will be approached three years from now. The audience will be polled on how difficult it may be to implement patient management strategies of the future into practice.

    Chairs:

    Hearn Jay Cho, MD, PhD
    Multiple Myeloma Research Foundation (MMRF)
    Norwalk, CT

    Paul G. Richardson, MD
    Harvard Medical School, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute
    Boston, MA

    A. Keith Stewart, MBChB
    University of Toronto, Princess Margaret Cancer Centre, University Health Network
    Toronto, ON, Canada

    Speakers:

    Amrita Y. Krishnan, MD
    Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Medical Center
    Duarte, CA

    Elisabet E. Manasanch, MD
    The University of Texas MD Anderson Cancer Center
    Houston, TX

    Nina Shah, MD
    University of California San Francisco
    San Francisco, CA

    Karen Tenaglia , RedMedEd
    Email: ktenaglia@redmeded.com


    A is for Antibody in Multiple Myeloma: Practical Insights and Patient Voices Along the Therapeutic Journey

    This program is supported by educational grants from GlaxoSmithKline, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Sanofi Genzyme.


    7:00 a.m. - 10:00 a.m. Eastern time
    Hyatt Regency Atlanta
    Centennial 3- Ballroom Level

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    This PeerView “Clinical Consults” live symposium and web broadcast, developed in collaboration with HealthTree Foundation, features real-world cases in newly diagnosed and relapsed/refractory disease to illustrate the practicalities and clinical uses of novel antibody platforms in MM. Each case discussion will be accompanied by a mini lecture designed to focus on clinically relevant evidence supporting the use of CD38, SLAMF7, and BCMA antibodies and include perspectives from MM patients on how treatment with novel antibodies has made a difference in their lives. Register today to participate in this expert-led program that will combine practical guidance on using antibody therapy in MM with insights from the patient’s therapeutic journey!

    Chair:

    Suzanne Lentzsch, MD, PhD
    Columbia University Medical Center
    New York, NY

    Speakers:

    Noa Biran, MD
    Hackensack University Medical Center, The John Theurer Cancer Center
    Hackensack, NJ

    Ajay K. Nooka
    Winship Cancer Institute, Emory University School of Medicine
    Atlanta, GA

    Margaret Walker , PVI, PeerView Institute for Medical Education
    Email: margaret.walker@peerview.com

    ACCESS PROGRAM HERE


    Acute Myeloid Leukemia: Evidence-Based Guidance on Current Paradigms and New Therapeutic Approaches

    This program is supported by Abbvie; Bristol Myers Squibb; Genentech, a member of the Roche Group


    7:00 a.m. - 10:00 a.m. Eastern time
    Atlanta Marriott Marquis
    Atrium A

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    This CME/CNE/CPE-certified satellite symposium, developed by NCCN, will feature reviews of the latest clinical data, NCCN Guidelines updates, and practical management recommendations for different patient case scenarios. Renowned experts in acute myeloid leukemia (AML) will provide their perspectives on recent changes in AML treatment and the rationale for the development of new and novel targeted treatment options that are individualizing the care of patients with AML. Engagement with the presenting faculty will be accomplished through audience response technology that allows attendees to not only answer case and polling questions, but also directly text questions and comments to the experts. In addition, the faculty will highlight the latest updates to the NCCN Guidelines and provide their practical clinical insights to enhance the implementation of new findings into practice upon returning home from the ASH annual meeting. Panel discussions to include:

    • Selecting Therapy for AML Without Predictive Biomarkers or Therapeutically Actionable Genomic or Molecular Alterations
    • Selecting Therapy for AML With Predictive Biomarkers or Therapeutically Actionable Genomic or Molecular Alterations
    • New and Novel Advances in AML Therapeutics—Future Approaches to BMT and Targeted Therapies

    Chair:

    Daniel A. Pollyea, MD, MS
    University of Colorado School of Medicine
    Aurora, CO

    Speakers:

    Amir T. Fathi, MD
    Massachusetts General Hospital Cancer Center
    Boston, MA

    Eunice S. Wang, MD
    Roswell Park Comprehensive Cancer Center
    Buffalo, NY

    Melanie Moletzsky , National Comprehensive Cancer Network
    Email: moletzsky@nccn.org


    Applying Guideline Updates and Real-World Experience in CLL: Experts Review State-of-the-Art Evidence and Address Clinical Challenges

    This program is supported by AstraZeneca; BeiGene, Ltd.; Genentech, a member of the Roche Group; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.


    7:00 a.m. - 10:00 a.m. Eastern time
    Atlanta Marriott Marquis
    Atrium B

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    This NCCN-developed satellite symposium presents a great opportunity for healthcare professionals to interact with experts and learn about the latest treatment advances in chronic lymphocytic leukemia (CLL). During the live event, the faculty will give an overview of recent advances in CLL covering risk assessment, molecular profiling, and current and emerging therapeutics. The symposium will also feature review of the latest updates to the NCCN guideline treatment algorithms to help guide practical application. This overview will be complemented by panel discussions of various patient case scenarios with expert recommendations and supporting clinical data. New developments on the near future horizon including the utility of measurable residual disease and ongoing clinical trials of promising investigational approaches will also be discussed. Time for audience questions and answers during the program will provide further perspectives on how the experts interpret the available clinical data and apply them in their practice. Learners will be provided with a networked all-in-one handheld device that enables them to fully interact, text, and directly contribute to the discussion throughout the symposium and to obtain further clarification on the data reviewed or expert perspective on their own treatment challenges.

    Chair:

    Asher Chanan-Khan, MBBS, MD
    Mayo Clinic
    Jacksonville, FL

    Speakers:

    Brian T. Hill, MD
    Cleveland Clinic
    Cleveland, OH

    Shuo Ma, MD
    Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine
    Chicago, IL

    Melanie Moletzsky , National Comprehensive Cancer Network
    Email: moletzsky@nccn.org


    Customizing Care in CLL With BTK Inhibitors: Evidence and Applications for Therapy Selection, Sequencing, and Safety Management

    This program is supported by an independent educational grant from AstraZeneca.


    7:00 a.m. - 10:00 a.m. Eastern time
    Hyatt Regency Atlanta
    Regency Ballroom VII- Ballroom Level

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    This PeerView “Clinical Consults” activity will feature expert-guided explorations of how BTK inhibitor use can be customized to achieve optimal CLL care according to changing circumstances, patient features, or safety considerations. The experts will utilize real-world clinical scenarios (supported by mini-lectures) designed to explore the most current evidence and clinical data related to the use of first- and second-generation BTK inhibitors and address topical issues such as: selectivity and safety differences between first- and second-generation BTK inhibitors; choosing a BTK option in treatment-naïve CLL; using phase 3 head-to-head safety evidence to guide therapy selection; agent sequencing in relapsed CLL and BTK-intolerant settings; and the management of BTK-related adverse events. Join our team of experts at the 2021 Annual Hematology Meeting for this exciting and highly practical event.

    Chair:

    John C. Byrd, MD
    University of Cincinnati College of Medicine
    Columbus, OH

    Speakers:

    Jacqueline Barrientos, MD, MS
    Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
    Lake Success, NY

    Kerry Rogers, MD
    The Ohio State University
    Columbus, OH

    Margaret Walker , PVI, PeerView Institute for Medical Education
    Email: margaret.walker@peerview.com

    ACCESS PROGRAM HERE


    Health Care Disparities in Blood and Marrow Transplantation: Issues and Potential Solutions

    This program is supported by Laura and Isaac Perlmutter Cancer Center, NYU Langone Health

    Diversity, Equity, and Inclusion


    7:00 a.m. - 10:00 a.m. Eastern time
    Atlanta Marriott Marquis
    Marquis Ballroom BCD

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    The theme of the symposium is health care disparity in blood and marrow transplantation (BMT), with an emphasis on:

    • The lack of donor options for recipients of certain ethnic groups and possible strategies to expand the pool of potential donors including the use of mismatched unrelated and haploidentical donors
    • Innovative strategies for graft-versus-host disease (GvHD) prevention to improve the results of mismatched unrelated and haploidentical donor transplants and increase the applicability of these approaches

    The purpose of the symposium is to raise providers’ awareness of these issues and stimulate interest in potential solutions. This program is supported by an educational grant from Bristol Myers Squibb.

    Chair:

    A Samer Al-Homsi, MD, MBA
    New York University Grossman School of Medicine
    New York, NY

    Speakers:

    Steven Devine, MD
    National Marrow Donor Program
    Minneapolis, MN

    Christopher G. Kanakry, MD
    National Cancer Institute
    Bethesda, MD

    Nicolaus Kroeger, MD
    University Medical Center Hamburg-Eppendorf
    Hamburg, Germany

    Muna Qayed, MD
    Emory University School of Medicine
    Atlanta, GA

    Laura Alice , NYU Langone Health
    Email: Laura.Alice@NYULangone.org


    MDS 2021: From Cutting Edge Definition of Disease to More Effective Treatments

    This program is supported by MDS Foundation, Inc.


    7:00 a.m. - 10:00 a.m. Eastern time
    VIRTUAL PROGRAM

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    The ASH 2021 MDS Foundation Symposium will deal with cutting edge definition of disease and more effective treatments for MDS patients. Speakers will illustrate the importance of a genetically-inspired classification of MDS in clinical decision making. Evidence will be presented that allogeneic transplantation can improve survival rates for older patients with higher-risk MDS. Discussion of representative clinical cases will emphasize that a patient-centered care model represents the best approach to the treatment of MDS patients.

    Chairs:

    Mario Cazzola, MD
    Fondazione IRCCS Policlinico San Matteo
    Pavia, Italy

    Rena J. Buckstein, MD
    Odette Cancer Centre, Sunnybrook Health Sciences Center
    Toronto, Canada

    Speakers:

    Elsa Bernard, PhD
    Center for Molecular Oncology, Center for Heme Malignancies and Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    New York, NY

    Luca Malcovati, MD
    IRCCS Policlinico S. Matteo Foundation
    Pavia, Pavia, Italy

    Moshe Mittelman, MD
    Tel Aviv Sourasky (ichilov) Medical Center
    Tel Aviv, Israel

    Ghulam J. Mufti, OBE DM FRCP FRCPath CPath
    King's College London
    London, United Kingdom

    David A. Sallman, MD
    H. Lee Moffitt Cancer Center
    Tampa, FL

    Zhuoer Xie, MD,MS
    Mayo Clinic
    Rochester, MN

    Lea Harrison , MDS Foundation, Inc.
    Email: lharrison@mds-foundation.org

    ACCESS PROGRAM HERE


    Resuscitating a Dying Marrow: Emerging Concepts and Treatment Advances in Myeloid Malignancies

    This program is supported by Cleveland Clinic & Aplastic Anemia and MDS International Foundation


    7:00 a.m. - 10:00 a.m. Eastern time
    VIRTUAL PROGRAM

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    The Cleveland Clinic Taussig Cancer Institute and the AA & MDS International Foundation join together to present a live and enduring continuing medical education activity focusing on myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN) and related myeloid malignancies. This CME-certified activity will provide an in-depth and up-to-date review of research related to the biology, prognosis, natural history, and therapeutic management of patients with myeloid malignancies including aplastic anemia, MDS, AML, MPN and related myeloid malignancies. The overall goal of the program is to bring together leaders in disease research and clinical practice to explore solutions to improving the care of these patient populations.

    Chair:

    Bhumika J. Patel, MD
    Cleveland Clinic
    Cleveland, OH

    Speakers:

    Seth J. Corey, MD, MPH
    Cleveland Clinic
    Cleveland, OH

    Mark Juckett, MD
    University of Minnesota Medical School
    Minneapolis, MN

    Sudipto Mukherjee, MD,PhD,MPH
    Cleveland Clinic Taussig Cancer Institute
    Cleveland, OH

    Gert Ossenkoppele, MD, PhD
    Amsterdam University Medical Centers
    Amsterdam, Netherlands

    Naveen Pemmaraju, MD
    The University of Texas MD Anderson Cancer Center
    Houston, TX

    Antonio Risitano, MD, PhD
    A.O.R.N. MOSCATI
    Avellino, Italy

    Yogenthiran Saunthararajah, MD
    Cleveland Clinic
    Cleveland, OH

    Kristin Bower , Cleveland Clinic
    Email: bowerk@ccf.org


    Seizing Opportunity in AML: How to Realize the Potential of Novel Therapeutics in Diverse Patient Populations

    This program is supported by independent educational grants from Astellas Pharma Global Development, Inc. and Jazz Pharmaceuticals, Inc.


    7:00 a.m. - 10:00 a.m. Eastern time
    Hyatt Regency Atlanta
    Centennial 4- Ballroom Level

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    Multiple recent regulatory approvals of novel therapeutics in acute myeloid leukemia (AML) have brought on a fundamental break with the previous treatment era, which was defined by the widespread use of cytarabine-based therapy and, to a lesser extent, certain lower-intensity agents. Currently, clinicians can seize the opportunity offered by this decisive change and address the needs of diverse AML patient populations by judiciously selecting personalized and highly effective treatment.

    This live CME/MOC-certified Seminars and Tumor Board educational event will reflect the recent changes in AML by convening a panel of leading hematology-oncology experts. The panelists, mimicking real-world tumor boards, will use a series of cases to illustrate the importance of accurate assessment of baseline factors and collaboration with other disciplines when making treatment choices. From there, the panelists will link therapeutic decision-making to the science that has shown improved patient outcomes are possible across the spectrum of AML, including in high-risk/poor prognosis, mutation-defined, and postremission settings. This unique educational offering will allow professional learners to “seize the day” in AML and effectively integrate novel cytotoxic, targeted, epigenetic, and antibody-based approaches into their practice. Register today for this exciting event!

    Chair:

    Naval Daver, MD
    MD Anderson Cancer Center
    Houston, TX

    Speakers:

    Uma Borate, MD
    The Ohio State University
    Columbus, OH

    Courtney D. DiNardo, MD, MSCE
    The University of Texas MD Anderson Cancer Center
    Houston, TX

    Eytan M. Stein, MD
    Memorial Sloan Kettering Cancer Center
    New York, NY

    Margaret Walker , PVI, PeerView Institute for Medical Education
    Email: margaret.walker@peerview.com

    ACCESS PROGRAM HERE


    Taking the Turn to Treatment Innovation in DLBCL: Real-World Insight on Integrating Antibodies and Cellular Therapy into Patient Care

    This program is supported by educational grants from ADC Therapeutics America; Genmab US, Inc.; Incyte Corporation; Kite, a Gilead Company, and MorphoSys US Inc.


    7:00 a.m. - 10:00 a.m. Eastern time
    Hyatt Regency Atlanta
    Centennial 2- Ballroom Level

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    PeerView’s “Clinical Consults” live event will be led by DLBCL experts and will focus on the implications of this therapeutic revolution for clinical practice. Using a series of alternating case-based discussions and mini-lectures, the experts will explore the science and practice of novel antibodies and CAR-T cell therapy, including: the identification of candidates for treatment with novel antibodies or cellular therapy; the principles of therapeutic sequencing; and appropriate safety management and monitoring strategies. By providing clear guidance on the use of CD19, CD79, and CD20-directed antibodies and CAR-T options in relapsed/refractory DLBCL, this event will be a powerful learning resource for clinicians. Join our experts at the 2021 Annual Hematology Meeting!

    Chair:

    Grzegorz (Greg) Nowakowski, MD
    Mayo Clinic
    Rochester, MN

    Speakers:

    Paolo F. Caimi, MD
    Cleveland Clinic Lerner College of Medicine, Case Comprehensive Cancer Center
    Cleveland, OH

    Peter A. Riedell, MD
    University of Chicago
    Chicago, IL

    Margaret Walker , PVI, PeerView Institute for Medical Education
    Email: margaret.walker@peerview.com

    ACCESS PROGRAM HERE


    Targeted Therapies in CLL/SLL: Treatment Sequencing and Adverse Events Management

    This program is supported by Lymphoma Research Foundation


    7:00 a.m. - 10:00 a.m. Eastern time
    Georgia World Congress Center
    Thomas Murphy Ballroom 3-4, Level 5

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    B-cell non-Hodgkin lymphoma (NHL) management has advanced significantly in recent years, and patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have been beneficiaries of these advances. However, studies have shown that as many as 40% of patients with CLL/SLL undergoing treatment with novel agents discontinue therapy, the majority of which are due to adverse events (AEs), and data suggest that the management of AEs is not consistent with recommendations. Moreover, despite advances in treatment, many patients will relapse, and subsequent treatment decisions are challenging. Real-world and prospective data regarding the impact of treatment sequence on patient outcomes are just emerging, and there is no guidance on sequencing therapies for patients who discontinue first-line therapy due to toxicity or progression.

    To help hematologist-oncologists keep pace with recommended AE management strategies and emerging data for treatment sequencing, this CME-certified FSS will consist of evidence-based presentations interspersed with real-world patient cases designed to provide learners with expert faculty insights and analysis of the clinical implications of new and emerging data for minimizing treatment-emergent AEs and managing treatment sequencing decisions in patients with CLL/SLL.

    Chair:

    Lindsey E. Roeker, MD
    Memorial Sloan Kettering Cancer Center
    New York, NY

    Speakers:

    Joanna M Rhodes, MD, MSCE
    CLL Research and Treatment Program, Northwell Health Cancer Institute; Donald and Barbara Zucker School of Medicine
    Lake Success, NY

    Chaitra S. Ujjani, MD
    University of Washington/Fred Hutchinson Cancer Research Center
    Seattle, WA

    Tarun Wasil, MBBS
    Currently in Solo Practice, Affiliated with Northwell Health, St. Francis Hospital, Winthrop Hospital
    New Hyde Park, NY

    Heather Rafa , RedMedEd
    Email: hrafa@redmeded.com


    The Evolution of Sickle Cell Disease: Current Advances and Future Possibilities

    This program is supported by independent educational grants from Agios Pharmaceuticals, Inc., Forma Therapeutics, and Novartis Pharmaceuticals Corporation.


    7:00 a.m. - 10:00 a.m. Eastern time
    Omni Atlanta Hotel at CNN Center
    Grand Ballroom E- North Tower M4

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    The therapeutic management of sickle cell disease (SCD) is evolving at a rapid pace. Several new agents, including agents targeting SCD vasculopathy and sickle cell–endothelial adhesive events, have been recently approved in the SCD therapeutic landscape and several emerging antisickling agents are in clinical studies that are poised to transform clinical practice in this disease. With increasing treatment options, it is more important than ever that clinicians remain abreast of recent clinical evidence on approved and emerging therapies. During this live CME/MOC/NCPD/CPE symposium/web broadcast, a panel of experts will offer physicians the recent clinical evidence to actualize these clinical and research advances into improved outcomes for patients with SCD. Our expert panel will discuss current and novel emerging therapeutic options for SCD, and provide strategies for interprofessional collaboration and patient engagement in routine clinical practice. After the lectures, a final case-based practicum segment will focus on the practical aspects of integrating innovative therapies for managing patients with SCD. Join us in person or online for this lively discussion!

    Chair:

    Biree Andemariam, MD
    University of Connecticut Health
    Farmington, CT

    Speakers:

    Matthew M. Heeney, MD
    Dana-Farber/Boston Children’s Cancer and Blood Disorders Center Harvard Medical School
    Boston, MA

    Abdullah Kutlar, MD
    Augusta University
    Augusta, GA

    Santosh L. Saraf, MD
    University of Illinois Hospital & Health Sciences System
    Chicago, IL

    Margaret Walker , PVI, PeerView Institute for Medical Education
    Email: margaret.walker@peerview.com


    The Road to Cures Through Immunotherapy and Precision Medicine

    This program is supported by The Leukemia & Lymphoma Society


    7:00 a.m. - 10:00 a.m. Eastern time
    VIRTUAL PROGRAM

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    The Friday Satellite Symposium, "The Road to Cures Through Immunotherapy and Precision Medicine," will directly address the most relevant information available at the time of the presentation with regard to:

    • CAR-T Therapy: What's in the CARds?
    • AML 2021: Strategies for Attack Before Diagnosis and After Remission
    • Efficacy of Targeted Therapy in Genetic Subtypes of Aggressive Lymphoma
    • Novel Therapeutic Strategies in Myeloma
    • COVID-19, Vaccinations, and Blood Cancer Patients: The LLS Registry

    Chair:

    Kenneth C. Anderson, MD
    The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
    Boston, MA

    Speakers:

    Kenneth C. Anderson, MD
    The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
    Boston, MA

    Lee Greenberger, PhD
    The Leukemia & Lymphoma Society
    Rye Brook, NY

    Carl H June, MD
    The University of Pennsylvania, Perelman School of Medicine
    Philadelphia, PA

    Gail J. Roboz, MD
    Weill Cornell Medicine/New York Presbyterian Hospital
    New York, NY

    Larry A Saltzman, MD
    The Leukemia & Lymphoma Society
    Rye Brook, NY

    Louis M. Staudt, MD, PhD
    National Cancer Institute, National Institutes of Health
    Bethesda, MD

    Cherie Haley , RMEI Medical Education, LLC
    Email: chaley@rmei.com


    Unlocking the Benefits of CAR-T Therapy in Hematologic Malignancies: Latest Evidence and Practical Considerations for Delivering State-of-the-Art Care

    This program is supported by independent educational grants from Kite, A Gilead Company; Legend Biotech; and Novartis Pharmaceuticals Corporation.


    7:00 a.m. - 10:00 a.m. Eastern time
    Hyatt Regency Atlanta
    Centennial 1- Ballroom Level

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    This unique and interactive symposium will offer learners a window into practice by featuring a series of expert-led lectures that will seamlessly link the latest scientific evidence on CAR-T therapy across a range of hematologic malignancies with panel-based insights on clinical decision-making. Each session will include a Tumor Board segment designed to reflect real-world clinical experiences and decision challenges, from identifying patient candidates to appropriate follow-up and the management of a unique spectrum of adverse events.

    Chair:

    Caron Jacobson, MD
    Harvard Medical School, Dana-Farber Cancer Institute
    Boston, MA

    Speakers:

    Caitlin Costello, MD
    UC San Diego Health, Moores Cancer Center
    La Jolla, CA

    Shannon L. Maude, MD, PhD
    The Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania
    Philadelphia, PA

    Alison R. Sehgal, MD
    University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center
    Pittsburgh, PA

    Margaret Walker , PVI, PeerView Institute for Medical Education
    Email: margaret.walker@peerview.com

    ACCESS PROGRAM HERE


    Untangling Amyloidosis 2021 - What Every Hematologist Ought to Know

    This program is supported by Barbara Ann Karmanos Cancer Institute


    7:00 a.m. - 10:00 a.m. Eastern time
    Georgia World Congress Center
    A411-A412, Level 4

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    The Karmanos Cancer Institute, in collaboration with the Amyloidosis Foundation and Amyloidosis Support Groups, Inc., is developing a CME symposium to be conducted on Friday, December 10th, 2021, preceding the annual American Society of Hematology (ASH) meeting. It will consist of a case-based series of presentations focused on the diagnosis, pathophysiology, and treatment of systemic amyloidosis, with a particular emphasis on AL amyloidosis. Recent advances in the therapy of all types of amyloidosis will be discussed during symposium. Invited speakers will present a clinical vignette which raises questions or illustrates key points related to the assigned topic. Given the importance of multidisciplinary management of amyloidosis, the invited speakers include amyloidosis experts from the fields of hematology, cardiology, and nephrology. Further, we intend to live-stream the presentations to expand the audience beyond those attending the ASH Annual Meeting. The program is intended to be interactive, and the audience will be asked to provide opinions and answers to questions intermittently throughout the program via Sync System. Panel discussions after the speakers' presentations will provide an opportunity to address questions from the live audience.

    Chair:

    Jeffrey A. Zonder, MD
    Karmanos Cancer Institute
    Detroit, MI

    Speakers:

    Angela Dispenzieri, MD
    Mayo Clinic
    Rochester, MN

    Andrea Havasi, MD
    Boston University School of Medicine
    Boston, MA

    Daniel P Judge, MD
    Medical University of South Carolina
    Charlston, SC

    Efstathios Kastritis, MD
    Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine
    ATHENS, Greece

    Paolo Milani, MD,PhD
    Foundation IRCCS Policlinico San Matteo, University of Pavia
    Pavia, Italy

    Jason Valent
    Cleveland Clinic
    Cleveland, OH

    Silva Pregja , Karmanos.Cancer Institute
    Email: pregjas@karmanos.org


    WHAT CLINICIANS WANT TO KNOW: Addressing Current Questions and Controversies in the Management of Chronic Lymphocytic Leukemia (Part 1 of a 4-part CME/MOC-accredited Symposia Series)

    This program is supported by Abbvie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb, Genentech, a member of Roche Group, Lilly, Pharmacyclics LLC, An AbbVie Co, Janssen Biotech Inc/Scientific Affairs LLC, & TG Therapeutics.


    7:00 a.m. - 10:00 a.m. Eastern time
    Omni Atlanta Hotel at CNN Center
    International Ballroom E-F, M2/International Ballroom Level

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    This CME/MOC program, part 1 of a 4-part series, will focus on the management of chronic lymphocytic leukemia. Five investigators will serve as the program’s faculty, one of whom will moderate the event. Prior to the program, Research To Practice (RTP) will recruit 5 general medical oncologists and hematologists to help frame the program’s content and agenda. RTP will work with these individuals to identify specific challenging clinical situations or questions from their practice for which they would seek input from an investigator. These clinicians will participate in a Working Group session during which their questions will be presented. The session will be video-recorded, and RTP will select excerpts for presentation at the live meeting. The agenda for the symposium will be divided into 5 modules, each featuring the presentation and discussion of video excerpts from the Working Group and a faculty member-led presentation formally reviewing emerging research relevant to the issues being presented. To make the event even more relevant, attendees will participate in surveys related to the topics, questions and cases discussed. Polling results will be interspersed throughout the event to foster additional debate.

    Chair:

    John N. Allan, MD, PhD
    Weill Cornell Medicine
    New York, NY

    Speakers:

    Nitin Jain, MD
    MD Anderson Cancer Center
    Houston, TX

    Anthony R. Mato, MD
    Memorial Sloan Kettering Cancer Center
    New York, NY

    John M. Pagel, MD, PhD
    Swedish Cancer Institute
    Seattle, WA

    Jennifer A. Woyach, MD
    The Ohio State University
    Columbus, OH

    Sylvia Eriksen , Research To Practice
    Email: meetings@researchtopractice.com


  • 2

    Early Afternoon Symposia

    11:00 a.m. - 2:00 p.m.
    Eastern time

    ACHIEVING INNOVATION IN CLL CARE: Evidence-Informed Choices With Targeted Options and Next Steps in Disease Management

    This program is supported by independent educational grants from AbbVie, AstraZeneca, BeiGene, Ltd., and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.


    11:00 a.m. - 2:00 p.m. Eastern time
    Omni Atlanta Hotel at CNN Center
    Grand Ballroom E- North Tower M4

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    Continuous or fixed-duration therapy with targeted agents (including BTK, PI3K, and BCL-2 inhibitors) in chronic lymphocytic leukemia (CLL) has overturned the decades-long consensus centered on immunochemotherapy and decisively become the new standard of care. When developing optimized regimens for patients, clinicians can now personalize treatment choices by selecting among targeted strategies or within potent drug classes. Future novel combinatorial approaches in CLL are also likely to usher in an era of potent, effective strategies with the ability to induce deeper and more durable responses.

    In collaboration with the CLL Society, this CME-certified live Seminars and Tumor Board event will feature a panel of leading CLL experts who, mimicking the collaborative nature of real-world tumor boards, will blend serial, case-based discussion with mini seminars designed to illustrate how fully integrating targeted therapeutics—including BTK, PI3K, and BCL-2 inhibitors, as well as novel antibodies—can improve care across the clinical spectrum of CLL. Panelists will cover important clinical topics such as the personalized, evidence-based selection of upfront treatment strategies, therapeutic sequencing in progressive disease settings, safety management and distinctions among agent classes, and next-generation and novel combinatorial strategies. Throughout, the experts will profile tools and resources from the CLL Society that can be used to enhance patient care. Register today for this exciting event!

    Chair:

    John Gribben, MD, DSc, FRCP, FRCPath, FMedSci
    Barts Cancer Institute, Barts and The London School of Medicine, Queen Mary, University of London
    London, United Kingdom

    Speakers:

    Farrukh T. Awan, MD
    UT Southwestern Medical Center
    Dallas, TX

    Thomas J. Kipps, MD, PhD
    Moores Cancer Center, University of California, San Diego
    La Jolla, CA

    Nicole Lamanna, MD
    Columbia University Medical Center, New York-Presbyterian/Columbia University Medical Center
    New York, NY

    Margaret Walker , PVI, PeerView Institute for Medical Education
    Email: margaret.walker@peerview.com

    ACCESS PROGRAM HERE


    Adapting Clinical Practice to a Rapidly Changing Therapeutic Landscape in Multiple Myeloma

    This program is supported by educational grants from Bristol-Myers Squibb, Genentech, a member of the Roche Group, GlaxoSmithKline, Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC, Karyopharm Therapeutics, Oncopeptides and Sanofi Genzyme.


    11:00 a.m. - 2:00 p.m. Eastern time
    Atlanta Marriott Marquis
    Marquis Ballroom BCD

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    Attendees of the annual International Myeloma Foundation/Clinical Care Options cosponsored symposium will be able to interact with a panel of international experts as they discuss the evolving therapeutic advances for patients with multiple myeloma (MM) and how they are integrating these approaches in their own clinical practice.

    Brian G.M. Durie, MD; Thomas G. Martin, MD; Philippe Moreau, MD; S. Vincent Rajkumar, MD; and Jesús F. San-Miguel, MD, PhD, will debate current clinical questions, discuss available evidence and challenges that affect therapeutic decisions, and highlight emerging treatment options for patients with MM. They will share their individual treatment recommendations for a series of patient cases while attendees vote on these case scenarios and compare their answers with the experts’. Attendees will also be able to text questions directly to the panel for discussion throughout the symposium.

    Topics will include:

    • Evidence for Treating High-Risk Smoldering MM
    • Current Therapeutic Strategies for Newly Diagnosed MM
    • Tailoring Management for Patients With MM in First Relapse
    • Expert Guidance for Treatment After Multiple Relapses
    • Evolving Role for BCMA-Targeted Therapies
    • Future Directions in MM Care: Emerging Agents and Spotlight of Key Abstracts From ASH 2021
    • Program Summary and Introduction to the 2022 MM Care Algorithm

    Chair:

    Brian G.M. Durie, MD
    Cedars-Sinai Outpatient Cancer Center
    Los Angeles, CA

    Speakers:

    Thomas Martin
    UCSF Helen Diller Family Comprehensive Cancer Center
    San Francisco, CA

    Philippe Moreau, MD,PhD
    University Hospital Hôtel-Dieu, Nantes
    Nantes, France

    S. Vincent Rajkumar, MD
    Mayo Clinic
    Rochester, MN

    Jesus San-Miguel
    Clínica Universidad De Navarra
    Pamplona, Spain

    Clinical Care Options , Meetings Department
    Email: meetings@clinicaloptions.com


    Advances in CAR-T Cell Therapy Across Hematologic Malignancies: From Pipeline to Clinical Practice

    This program is supported by an educational grant from Bristol-Myers Squibb. Provided by Clinical Care Options, LLC.


    11:00 a.m. - 2:00 p.m. Eastern time
    Atlanta Marriott Marquis
    Atrium A

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    CAR T-cell therapy is at forefront of advances in the treatment of relapsed or chemotherapy-refractory leukemia, lymphoma, and myeloma. In this symposium, experts in these malignancies will use a case-based approach to examine current and emerging applications for CAR T-cell therapy, discussing key clinical data and providing their expert insights to maximize efficacy while appropriately managing toxicity. Throughout the symposium, attendees will interact with the experts using text-friendly audience response technology and will be introduced to proprietary interactive clinical tools for adverse event management. After each presentation, faculty will pause for a panel discussion and to answer questions from the audience. Discussion topics include:

    • CAR T-cell therapy in lymphomas
    • CAR T-cell therapy for myeloma
    • CAR T-cell therapies for R/R (R/R) acute lymphoblastic leukemia (ALL)
    • Effectively identifying and managing unique CAR T-cell–mediated adverse events

    Chair:

    Michael R. Bishop, MD
    University of Chicago
    Chicago, IL

    Speakers:

    Jesús G. Berdeja
    Sarah Cannon Research Institute
    Nashville, TN

    Jae H Park, MD
    Memorial Sloan-Kettering Cancer Ctr.
    New York, NY

    Clinical Care Options , Meetings Department
    Email: meetings@clinicaloptions.com


    Advances in Immune Thrombocytopenia: Expert Guidance to Navigate an Evolving Therapeutic Landscape

    This program is supported by educational grants from Amgen, Dova Pharmaceuticals, Inc., and Sanofi Genzyme. Provided by Clinical Care Options, LLC.


    11:00 a.m. - 2:00 p.m. Eastern time
    Atlanta Marriott Marquis
    Atrium B

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    New science has driven innovative medical practice in the recognition and management of immune thrombocytopenia (ITP). This symposium, focused on new advances and the latest research progress in ITP, will be balanced by practical expert guidance on current therapeutic strategies for initial and second-line treatment. The symposium agenda will include didactic data presentations by experts with case challenges, moderated panel discussion, and audience interactivity with ample time for questions and answers. Along with the experts, audience learners will explore key clinical questions, available evidence, and challenges that affect therapeutic decisions as well as receive personal expert treatment recommendations for each case. Throughout the symposium, learners will be able to vote on case scenarios and text questions to the panel for their consideration. Discussion topics will include:

    • Initial Management of ITP: Diagnosis and Treatment Considerations
    • Clinical Application of New Advances in the Management of Refractory ITP
    • Caring for Special Populations of Patients With ITP/Thrombocytopenia
    • 2022 Clinical Algorithm for the Management of ITP

    Chair:

    Keith R. McCrae, MD
    Cleveland Clinic
    Cleveland, OH

    Speakers:

    Nichola Cooper, MD
    Hammersmith Hospital, Imperial College London
    London, United Kingdom

    Rachael F. Grace, MD
    Children's Hospital Boston
    Boston, MA

    Clinical Care Options , Meetings Department
    Email: meetings@clinicaloptions.com


    Advances in the Therapeutic Management of Patients with Chronic Hematological Conditions- A Whiteboard Preceptorship

    This program is supported by Novo Nordisk


    11:00 a.m. - 2:00 p.m. Eastern time
    Georgia World Congress Center
    Thomas Murphy Ballroom 1-2, Level 5

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    Recent advances in treatment strategies promise to improve the lives of patients with sickle cell disease or hemophilia. In this program, experts in both fields will assist clinicians in developing individualized management plans using state-of-the-art and emerging therapies, and highlight opportunities to implement multidisciplinary, patient-centered approaches to care. Case studies and interactive question and answers will provide learners practice in applying patient-specific factors to treatment decisions. This activity will feature whiteboard animations that will reinforce learning and help participants gain a higher level of understanding.

    Speakers:

    Martin H. Steinberg, MD
    Professor of Medicine, Boston University School of Medicine
    Boston, MA

    Michael White, MD, MSC
    Pediatric Hematology/Oncology, Aflac Cancer & Blood Disorders Center Children’s Healthcare of Atlanta Assistant Professor of Pediatrics, Emory University School of Medicine
    Atlanta, GA

    John Guerriero , Med Learning Group
    Email: john.guerriero@medlearninggroup.com

    ACCESS PROGRAM HERE


    Aware of the Rare: The New Dawn! Updates in Diagnosing and Managing Rare Hematologic Disorders

    This program is supported by Blueprint Medicines, Novartis Oncology, Rigel Pharmaceuticals, Inc.


    11:00 a.m. - 2:00 p.m. Eastern time
    Omni Atlanta Hotel at CNN Center
    Grand Ballroom ABC, M4/Grand Ballroom Level

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    During this symposium, participants will be presented with case-based scenarios on rare hematologic disorders that challenge them to make decisions that lead to optimal outcomes. Using an interactive, gaming approach, participants will have the opportunity to continually and actively engage with symposium content. The format is designed to closely replicate the real-life physician’s experience of treating patients with rare hematologic disorders. As such, with expert faculty input, the following topics may be discussed in relation to hematologic disorders:

    • Pathophysiology of disease
    • Establishing a diagnosis and recognizing differential diagnoses
    • Traditional approaches to treatment, including mechanisms of action (MOAs), strengths, and limitations
    • Key clinical trial data for newer (current and emerging) treatments: MOA, efficacy, safety, strengths, limitations, real-world data
    • Key considerations in treatment selection – How do we personalize care?
    • Strategies for improving overall patient care
    • Collaborating with the multidisciplinary team

    Chair:

    Andrew Provan
    Barts and The London School of Medicine and Dentistry
    London, United Kingdom

    Speakers:

    Daniel J. DeAngelo, MD, PhD
    Dana-Farber Cancer Institute
    Boston, MA

    Morag Griffin, MD
    Department of Haematology, Leeds Teaching Hospitals NHS Trust
    Leeds, United Kingdom

    Alexander Roeth, MD
    Essen University Hospital
    Essen, Germany

    Kristen Holt Holt Gresham , Medscape
    Email: kholt@webmd.net


    Cases and Conversations™: Modifying the Course of Sickle Cell Disease with Modern Interventions

    This program is supported by an educational grant from Global Blood Therapeutics, Inc.


    11:00 a.m. - 2:00 p.m. Eastern time
    Hyatt Regency Atlanta
    Centennial 2

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    This PER® Cases and Conversations™ program features a panel of experts who will discuss strategies for the management of patients with sickle cell disease. Using patient case examples, these experts will present the most recent evidence for developing a comprehensive medical approach for these patients, and what this approach looks like in clinical practice.

    Chairs:

    Kenneth I. Ataga, MD
    UTHSC Center for Sickle Cell Disease
    Memphis, TN

    Elliott Vichinsky, MD
    UCSF Benioff Children’s Hospital Oakland
    Oakland, CA

    Speakers:

    Modupe Idowu, MD
    University of Texas McGovern Medical School
    Houston, TX

    Caterina P. Minniti, MD
    Albert Einstein College of Medicine
    Bronx, NY

    Phil Talamo , Physicians' Education Resource, LLC (PER)
    Email: ptalamo@gotoper.com

    ACCESS PROGRAM HERE


    Diagnosis and Treatment of MF and PV: Where Are We and Where Are We Going?

    This program is supported by grants from AbbVie; BMS; Constellation Pharmaceuticals, Geron Corporation, Incyte, PharmaEssentia USA; Protagonist Therapeutics, Inc.; Sierra Oncology, Inc.; & Sumitomo Dainippon Pharma Oncology, Inc.


    11:00 a.m. - 2:00 p.m. Eastern time
    Hyatt Regency Atlanta
    Centennial 1

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    This live program is designed to provide clinicians with the latest understanding of risk stratification and management principles for patients with PV and MF. This will include the latest information on molecular findings in these diseases, as well as emerging treatment options currently being developed. These topics will be incorporated into real-world case scenarios, where the panel of expert faculty will discuss challenging cases across the continuum of care. The overall goal of this program is to give participants the tools needed to make informed treatment decisions to individual patients with myeloproliferative neoplasms.

    Chair:

    Srdan Verstovsek, MD, PhD
    M.D. Anderson Cancer Center
    Houston, TX

    Speakers:

    Andrew T. Kuykendall, MD
    H. Lee Moffitt Cancer Center & Research Institute
    Tampa, FL

    Lindsey Lyle, MS, PA-C
    University of Colorado
    Aurora, CO

    Laura C. Michaelis, MD
    The Medical College of Wisconsin Inc.
    Milwaukee, WI

    Abdulraheem Yacoub, MD
    University of Kansas Cancer Center
    Westwood, KS

    Phil Talamo , Physicians' Education Resource, LLC (PER)
    Email: ptalamo@gotoper.com

    ACCESS PROGRAM HERE


    Elucidating Novel BTKi Strategies in CLL/SLL and MCL: A Virtual Exploration to Bring Therapeutic Rationales and Evidence into Perspective

    This program is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.


    11:00 a.m. - 2:00 p.m. Eastern time
    Hyatt Regency Atlanta
    Centennial 3

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    The live activity will feature a series of didactic presentations coupled with case presentations from prominent experts in the field that will be used as a starting point to discuss the latest data across CLL/SLL and MCL.

    • The activity is designed to highlight and test participants on the most clinically relevant data in CLL/SLL and MCL, provide expert guidance on the interpretation of core concepts, and forecast the clinical impact of recent data sets.
    • To enrich discussion and illuminate understanding of the evolution of BTK inhibition in liquid tumors, the program will feature a 2-3 minute video-based virtual exploration of the rationale and mechanism of action for BTK inhibitors in lymphoid malignancies. The video will be narrated by a faculty presenter and will be subsequently housed with the enduring activities.
    • The faculty panel will convene to share their own practice preferences and perspectives on the clinical trial data and share clinical pearls from their own practices.
    • To further enhance the integration of recent data into practice, the program will feature an interactive question-and-answer session with faculty throughout the activity to emphasize areas of educational need, highlighting areas of debate, and illustrating the application of new data in defined clinical situations.

    Chair:

    William G. Wierda
    MD Anderson
    Houston, TX

    Speakers:

    Peter Martin, FRCPC, MD, MS
    Weill Cornell Medical College-New York Presbyterian Hospital
    New York, NY

    Stephen J. Schuster, MD
    Lymphoma Program, Abramson Cancer Center, University of Pennsylvania
    Philadelphia, PA

    Michael Wang, MD
    U.T. M.D. Anderson Cancer Center
    Houston, TX

    Phil Talamo , Physicians' Education Resource, LLC (PER)
    Email: ptalamo@gotoper.com

    ACCESS PROGRAM HERE


    Experts Debate Treatment Decisions in Relapsed/Refractory Multiple Myeloma

    This program is supported by Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Legend Biotech, Oncopeptides, Inc., and Sanofi Genzyme


    11:00 a.m. - 2:00 p.m. Eastern time
    Georgia World Congress Center
    Georgia Ballroom 2, Level 3

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    The educational symposium will involve 4 faculty experts actively engaged in the care of patients with relapsed/refractory multiple myeloma. The satellite symposium will utilize an engaging, debate-style format in which expert faculty will cross-examine recent advances and current controversies in the treatment of relapsed/refractory multiple myeloma. The symposium will include polling questions, case-based discussions, short didactic sessions, and a Q&A, which will allow faculty to address participants’ most pressing clinical concerns. At the end of the symposium, faculty will highlight and reinforce the most important take-home messages for learners.

    Chair:

    Sagar Lonial, MD, FACP
    Emory University - Winship Cancer Institute
    Atlanta, GA

    Speakers:

    Jonathan L. Kaufman, MD
    Winship Cancer Institute of Emory University
    Atlanta, GA

    Krina K. Patel, MD,MSc
    University of Texas MD Anderson Cancer Center
    Houston, TX

    Saad Z. Usmani
    Memorial Sloan Kettering Cancer Center
    New York, NY

    Jennifer Bechan , Bio Ascend LLC
    Email: bechan@bioascend.com


    Gene Therapy and Hemophilia Care Updates: Bringing Your Treatment Center Up to Speed

    This program is supported by Pfizer and Spark Therapeutics


    11:00 a.m. - 2:00 p.m. Eastern time
    Omni Atlanta Hotel at CNN Center
    Grand Ballroom D1/D2

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    Advances in treatment have transformed hemophilia from a devastating and debilitating disease to one that can be managed. Despite these advances, many patients continue to face the burden of treatment and suffer morbidity from their disease. Gene therapy is uniquely positioned to potentially revolutionize the care of patients with hemophilia. Our expert panel will guide us in an interactive discussion on the advancements of gene therapy in hemophilia, including updates on clinical trials in hemophilia A and B, and will suggest strategies to help prepare for the implementation of gene therapy in hemophilia treatment centers.

    Chair:

    David Lillicrap, MD
    Queen's University Richardson Laboratory
    Kingston, ON, Canada

    Speakers:

    Kollet Koulianos, MBA
    National Hemophilia Foundation
    New York, DC

    Susan Lattimore
    Oregon Health & Science University
    Portland, OR

    Andrew D Leavitt, MD
    UCSF
    San Francisco, CA

    Kristen Holt Gresham , Medscape
    Email: kholt@webmd.net


    Overcoming Barriers to Equitable Care for Patients with Multiple Myeloma

    This program is supported by AbbVie, Inc ; Bristol-Myers Squibb


    11:00 a.m. - 2:00 p.m. Eastern time
    Georgia World Congress Center
    Thomas Murphy Ballroom 3-4, Level 5

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    The faculty panel will engage in extensive discussion around opportunities to improve care delivery, including engaging patients to be active members of their care team through shared decision making; supporting enrollment in MM clinical trials, when appropriate; and solving practical challenges related to health literacy, medication adherence, and other barriers to optimal patient outcomes. the faculty panel will utilize evidence slides featuring (a) real-world data on MM practice patterns, challenges, and action plans from phase 1 and 2 of the IS-IME initiative in system- and community-based oncology practices, respectively; (b) latest evidence and guidelines for relapsed/refractory MM; and (c) expert consensus strategies to engage patients with MM in SDM.

    Speakers:

    Sikander Ailawadhi, MD
    Mayo Clinic
    Jacksonville, FL

    Craig E. Cole, MD
    Michigan State University
    Lansing, MI

    Stinchon R Michael Jr., RPh
    United Healthcare
    Hartford, CT

    Tamara Gonzalez , PRIME Education LLC
    Email: t.gonzalez@primeinc.org


    WHAT CLINICIANS WANT TO KNOW: Addressing Current Questions and Controversies in the Management of Hodgkin and Non-Hodgkin Lymphoma (Part 2 of a 4-part CME/MOC-accredited Symposia Series)

    This program is supported by ADC Therapeutics, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation, Kite, A Gilead Company, Lilly, and Seagen Inc.


    11:00 a.m. - 2:00 p.m. Eastern time
    Omni Atlanta Hotel at CNN Center
    International Ballroom E-F, M2/International Ballroom Level

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    This CME/MOC program, part 2 of a 4-part series, will focus on the management of patients with Hodgkin and non-Hodgkin lymphoma. Five investigators will serve as faculty, one of whom will moderate the event. Prior to the program, Research To Practice (RTP) will recruit 5 general medical oncologists and hematologists to help frame the program’s content and agenda. RTP will work with these individuals to identify challenging clinical situations or questions from their practice for which they would seek input from an investigator. These clinicians will then participate in a Working Group session during which their questions will be presented. The session will be video-recorded and RTP will select excerpts for presentation during the live meeting. The symposium agenda will be divided into 5 modules, each featuring the presentation and discussion of video excerpts from the Working Group and a faculty member-led presentation formally reviewing emerging research relevant to the issues & scenarios presented. To make the event even more relevant, attendees will participate in a survey related to the topics, questions and cases discussed. Polling results will be interspersed throughout event to foster additional debate.

    Chair:

    Ann S. LaCasce, MD, MMSc
    Dana-Farber Cancer Institute
    Boston, MA

    Speakers:

    Jeremy S. Abramson, MD
    Massachusetts General Hospital Cancer Center
    Boston, MA

    Martin H. Dreyling, MD, PhD
    University Hospital
    Munich, DEU

    Loretta Nastoupil, MD
    The University of Texas MD Anderson Cancer Center
    Houston, TX

    Gilles Salles, MD,PhD
    Memorial Kettering Cancer Center
    New York, NY

    Sylvia Eriksen , Research To Practice
    Email: meetings@researchtopractice.com


  • 3

    Late Afternoon Symposia

    3:00 p.m. - 6:00 p.m.
    Eastern time

    New Targets, New Combinations, New Treatment Goals: Assessing Therapeutic Options to Personalize Care in Multiple Myeloma

    This program is supported by an educational grants from Amgen, Inc., Karyopharm Therapeutics, Legend Biotech USA, Inc., Oncopeptides, Sanofi Genzyme, Secura Bio, Inc., and Takeda Oncology.


    3:00 p.m. - 6:00 p.m. Eastern time
    Hyatt Regency Atlanta
    Centennial 3

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    This hybrid (live and virtual) symposium mainly uses clinical case discussions to provide insights from experts on the latest data from pivotal clinical trials on novel therapies in MM and on the optimal strategies to combine and sequence novel therapies, and to effectively manage treatment-related toxicities to optimize outcomes in patients with MM. Additionally, this symposium will also discuss the evidence regarding disparities in care in patients with MM of different racial and ethnic backgrounds, and strategies to address these disparities in care to improve outcomes in patients with MM.

    Chair:

    Ajai Chari, MD
    Mt. Sinai School of Medicine
    New York, NY

    Speakers:

    Sikander Ailawadhi, MD
    Mayo Clinic
    Jacksonville, FL

    Nizar J. Bahlis, MD
    University of Calgary
    Calgary, AB, Canada

    Neha Korde, MD
    Memorial Sloan Kettering Cancer Center
    New York, NY

    Cesar Rodriguez
    Wake Forest University School of Medicine
    Winston-Salem, NC

    Phil Talamo , Physicians' Education Resource, LLC (PER)
    Email: ptalamo@gotoper.com

    ACCESS PROGRAM HERE


    A Review of Current and Emerging Treatment Options for Myelodysplastic Syndromes

    This program is supported by educational grants from Abbvie Inc., Gamida Cell Ltd., Geron Corporation, Gilead Sciences Inc., Karyopharm Therapeutics Inc. and Takeda Pharmaceuticals U.S.A., Inc.: Takeda Oncology Company. Provided by Clinical Care Options, LLC.


    3:00 p.m. - 6:00 p.m. Eastern time
    Atlanta Marriott Marquis
    Atrium A

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    New science has driven innovative medical practice in the management of myelodysplastic syndromes (MDS) with hypomethylating agents (HMAs; including oral formulations), erythropoiesis-stimulating agents (ESAs), immunosuppressants, lenalidomide, and luspatercept. This symposium will focus on evolving therapeutic standards and emerging therapeutic options with expert faculty providing practical insights for disease and supportive care management of MDS. Using different case presentations, the experts will discuss key clinical questions, available supporting evidence, and challenges that affect therapeutic decisions as well as their individual treatment recommendations for each case. Throughout the symposium, learners will be able to vote on case scenarios and directly text questions to the panel for their consideration. Discussion topics will include:

    • Risk stratification in MDS
    • Managing anemia in very low–risk, low-risk, or intermediate-risk MDS
    • Novel therapeutic approaches for lower-risk MDS
    • Latest guidance on treating higher-risk MDS and managing relapsed/refractory MDS
    • Future directions on key clinical trials

    Chair:

    Michael R. Savona, MD
    Vanderbilt University School of Medicine; Ingram Cancer Center
    Nashville, TN

    Speakers:

    Jacqueline S. Garcia, MD
    Medical Oncology
    Boston, MA

    Amer M. Zeidan, MD
    Yale University School of Medicine
    East Haven, CT

    Clinical Care Options , Meetings Department
    Email: meetings@clinicaloptions.com


    Addressing Clinical Challenges in T-Cell Lymphomas Through Biomarker-Driven Therapy

    This program is supported by Supported by educational grants from Daiichi Sankyo, Inc., Kyowa Kirin, Seagen Inc. and Takeda Oncology. Provided by Clinical Care Options, LLC.


    3:00 p.m. - 6:00 p.m. Eastern time
    Atlanta Marriott Marquis
    Marquis Ballroom BCD

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    This symposium will feature presentations and panel discussions with perspectives and recommendations from multiple experts. In addition, the expert panel will address audience questions, challenges, and cases identified in the “Live Case and Question Submission” that are sent directly to the faculty. At the live symposium, all attendees will be provided with a networked IML connector (or online polling capability), an all-in-one handheld device that enables learners to fully interact in case management voting. Of importance, the IML technology is preferred over “standard ARS,” as it adds the ability for learners to submit questions to the expert faculty by text message, thereby directly contributing to the content and outcome of the symposium. This symposium format will provide an interactive way to disseminate cutting-edge information and expert perspectives to learners, while also addressing educational gaps related to the translation of practice-changing data into clinical practice.

    Chair:

    Steven M. Horwitz, MD
    Memorial Sloan Kettering Cancer Center
    New York, NY

    Speakers:

    Francine M. Foss, MD
    Yale Cancer Center
    New Haven, CT

    Barbara Pro, MD
    Northwestern University
    Chicago, IL

    Clinical Care Options , Meetings Department
    Email: meetings@clinicaloptions.com


    Adopting MRD Assessment for Hematologic Malignancies in Real-World Settings: Technique, Role, and Utilization to Improve Patient Outcomes

    This program is supported by educational grants from Adaptive Biotechnologies and Amgen, Inc.


    3:00 p.m. - 6:00 p.m. Eastern time
    Hyatt Regency Atlanta
    Centennial 2

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    The live portion of this curriculum will be presented as a 3-hour Friday Satellite Symposium (FSS) held prior to the ASH Annual Meeting. The live activity will feature a series of didactic presentations coupled with Medical Crossfire® from prominent experts in the field. To set the stage, a “Real World” interview with a community oncologist be used as a starting point to discuss the latest data for MRD monitoring and their implications for clinical practice.

    Chair:

    Jerald P. Radich, MD
    Professor, Medical Oncology Division University of Washington School of Medicine Clinical Research Division Fred Hutchinson Cancer Research Center
    Seattle, WA

    Speakers:

    Paolo Ghia, MD,PhD
    Professor Università Vita-Salute San Raffaele di Milano Director, Strategic Research Program on CLL IRCCS San Raffaele Scientific Institute
    Milan, Italy

    Irene M. Ghobrial, MD
    Dana-Farber Cancer Institute
    Boston, MA

    Lori Muffly, MD
    Assistant Professor of Medicine Bone & Marrow Transplantation Stanford University Medical Center
    Stanford, CA

    Mark Roschewski, MD
    Lymphoid Malignancies Branch, Center for Cancer Research National Cancer Institute, National Institutes of Health
    Bethesda, MD

    Phil Talamo , Physicians' Education Resource, LLC
    Email: ptalamo@gotoper.com

    ACCESS PROGRAM HERE


    Aligning the Evidence with the Patient to Individualize Treatment Considerations Along the CML Care Continuum

    This program is supported by an educational grants from Ascentage Pharma Group Inc., and Novartis Pharmaceuticals Corporation.


    3:00 p.m. - 6:00 p.m. Eastern time
    VIRTUAL PROGRAM

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    This virtual live program is designed to update clinicians on clinical trial data, such as long-term evidence and novel treatment options, impacting patient care. In addition, the case-based panel discussions will provide expert strategies for practical management, including monitoring treatment response, shared decision-making of therapeutic strategy, managing patients with resistance mutations and other complexities, considerations for therapy cessation, effective communication, and aligning the most recent evidence in a patient-centered, goal-concordant manner.

    Chair:

    Jorge E. Cortes, MD
    Georgia Cancer Center Augusta University
    Augusta, GA

    Speakers:

    Vivian G. Oehler, MD
    Fred Hutchinson Cancer Research Ctr.
    Seattle, WA

    Delphine Rea, MD,PhD
    Université de Paris, Hematology department, Saint-Louis hospital, APHP
    Paris, France

    Phil Talamo , Physicians' Education Resource, LLC (PER)
    Email: ptalamo@gotoper.com

    ACCESS PROGRAM HERE


    Are You Up To Date on Non-CAR T-Cell Strategies for R/R Diffuse Large B-Cell Lymphoma?

    This program is supported by Morphosys, Karyopharm, and Incyte


    3:00 p.m. - 6:00 p.m. Eastern time
    Omni Atlanta Hotel at CNN Center
    Grand Ballroom D1/D2

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    Outcomes for patients with diffuse large B-cell lymphoma (DLBCL) who relapse or are refractory (R/R) to first-line treatment are poor, especially those who are ineligible for progressed after stem cell transplantation. This activity will provide insights in the non-CAR T-cell treatment options available for this patient population in order to personalize and safely manage treatment and provide patients with the best care.

    Chair:

    Pier Luigi Zinzani, MD, PhD
    Istituto Di Ematologia
    Bologna, Italy

    Speakers:

    Andre H. Goy, MD
    John Theurer Cancer Center, Hackensack University Medical Center
    Hackensack, NJ

    Kami J. Maddocks, MD
    Ohio State University Hospital
    Columbus, OH

    Kristen Holt Gresham , Medscape
    Email: kholt@webmd.net


    Asparaginase-Based Treatments in Young and Older Adults With Acute Lymphoblastic Leukemia: Leveraging the Pediatric Experience

    This program is supported by educational grants from Jazz Pharmaceuticals, Servier Pharmaceuticals and Servier Oncology Global Medical and Patient Affairs. Provided by Clinical Care Options, LLC.


    3:00 p.m. - 6:00 p.m. Eastern time
    Atlanta Marriott Marquis
    Atrium B

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    Dose-intensified, multiagent chemotherapy regimens, in which asparaginase plays a prominent role, have substantially improved outcomes for children and adolescents/young adults (AYAs) with acute lymphoblastic leukemia (ALL) in recent decades and are playing an increasing role in adult and older adult patients. This symposium, focused on the latest evidence to optimize the care of older patients with ALL using asparaginase, will provide practical expert guidance on current therapeutic strategies for monitoring/identifying clinical and subclinical asparaginase hypersensitivity and the latest recommendations for patient management. The symposium agenda will include didactic data presentations by experts with case challenges, moderated panel discussion, and audience interactivity with ample time for Q&A. Along with the experts, audience participants will explore key clinical questions, available evidence, and challenges that affect therapeutic decisions as well as receive personal expert treatment recommendations for each case. Throughout the symposium, learners will be able to vote on case scenarios and directly text questions to the panel for their consideration. Discussion topics will include:

    • Overview of induction, consolidation, and maintenance treatment algorithms for ALL
    • Strategies to increase completion of asparaginase-based treatment
    • Leveraging the lessons and experience treating pediatric patients to optimize the care of AYA and adult patients with ALL

    Chair:

    Wendy Stock, MD
    University of Chicago Medicine
    Chicago, IL

    Speakers:

    Emily Curran, MD
    University of Cincinnati Cancer Institute
    Cincinnati, OH

    Dan Douer, MD
    Keck School of Medicine
    Los Angeles, CA

    Scott C Howard, MD,MSc
    University of Tennessee Health Science Center
    Memphis, TN

    Stephen Hunger, MD
    Children’s Hospital of Philadelphia
    Philadelphia, PA

    Clinical Care Options , Meetings Department
    Email: meetings@clinicaloptions.com


    Assessing the Potential of Gene Therapies for Hemoglobinopathies – The Importance of Long-Term Data

    This program is supported by Bluebird Bio, Inc.


    3:00 p.m. - 6:00 p.m. Eastern time
    Omni Atlanta Hotel at CNN Center
    Grand Ballroom E, M4/Grand Ballroom Level

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    Newly approved and emerging therapies for ß-thalassemia and sickle cell disease (SCD) have the potential to dramatically impact patient quality of life and health outcomes. This interactive educational program will address the long-term clinical evidence of gene therapy for hemoglobinopathies, discuss how gene therapy is implemented in clinical practice, and provide guidance on the management of patients as treatment paradigms evolve.

    Chair:

    Christine N. Duncan, MD
    Boston Children's Hospital, Harvard Medical School
    Boston, MA

    Speakers:

    Jeanne Boudreaux, MD
    Children's Healthcare of Atlanta, Emory University
    Atlanta, GA

    Janet L. Kwiatkowski, MD, MSCE
    Children's Hospital of Philadephia
    Philadelphia, PA

    Kristen Holt Holt Gresham , Medscape
    Email: kholt@webmd.net


    Cold Agglutinin Disease: Shifting the Treatment Paradigm through Improved Understanding of the Complement System

    This program is supported by an educational grant from Sanofi Genzyme.


    3:00 p.m. - 6:00 p.m. Eastern time
    Hyatt Regency Atlanta
    Centennial 4

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    This program will feature interactive discussions with expert hematologists and oncologists regarding the burden of CAD, the mechanism of disease, early disease identification and diagnosis, as well as the efficacy and safety of complement-mediated therapies for disease management. Case studies will be incorporated to allow the audience to garner expert insight into best practices and challenges in the diagnosis and treatment of patients with CAD. Through Q&A sessions, the audience will have the opportunity to ask questions of the experts regarding current clinical issues in CAD.

    Chair:

    Alexander Roeth, MD
    West German Tumor Center Essen
    Essen, Germany

    Speakers:

    Wilma Barcellini, MD
    Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico
    Milan, Italy

    Catherine M. Broome, MD
    MedStar Georgetown University
    Washington, DC

    Ilene C. Weitz, MD
    Keck School of Medicine, University of Southern California
    Los Angeles, CA

    Phil Talamo , Physicians' Education Resource, LLC (PER)
    Email: ptalamo@gotoper.com

    ACCESS PROGRAM HERE


    Gene Therapy for Hemophilia B: How Close Are We to a Cure?

    This program is supported by CSL Behring


    3:00 p.m. - 6:00 p.m. Eastern time
    Georgia World Congress Center
    Thomas Murphy Ballroom 1-2, Level 5

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    Treatments for hemophilia B are burdensome for patients and caregivers alike, often requiring lifelong daily intervention. Could gene therapy for hemophilia B change the treatment paradigm by offering a potential cure? Promising results from clinical trials are emerging, and healthcare providers (HCPs) will soon be faced with guiding their patients through the decision process—maintain an established but intrusive regimen, or switch to a novel, less burdensome, but still emerging, therapy? As part of shared decision-making, HCPs will need to understand and communicate potential benefits and risks, along with long-term safety and durability findings, and address patient concerns, needs, and barriers. Along with our expert patient and scientist, Radoslaw Kaczmarek, our faculty of clinicians will explore the rationale for gene therapy in hemophilia B, recent clinical trial data, and patient considerations.

    Recognizing that the patient is at the core of treatment decisions, this symposium places a patient with hemophilia B on the faculty panel to share his perspectives concerning gene therapy. Following a series of engaging didactic presentations incorporating audience interaction, participants will be encouraged to connect with the faculty and patient panelists throughout the program through collaborative questions and a dynamic panel discussion.

    Chair:

    Paul Batty, MBBS, PhD
    Queens University
    Kingston, ON, Canada

    Speakers:

    Paul Batty, MBBS, PhD
    Queens University
    Kingston, ON, Canada

    Bhavya S Doshi, MD
    University of Pennsylvania
    Philadelphia, PA

    Radoslaw Kaczmarek, PhD
    Indiana University School of Medicine
    Indianapolis, IN

    Annette von Drygalski, MD, Pharm D
    University of California San Diego
    San Diego, CA

    Amy Groves , Institute for Medical and Nursing Education, Inc.
    Email: amy.groves@imne.com

    ACCESS PROGRAM HERE


    Improving Outcomes and Quality of Life in

    ß

    -Thalassemia: Patient Perspectives and Expert Recommendations

    This program is supported by an educational grants from Agios Pharmaceuticals, Inc., and Bristol Myers Squibb.


    3:00 p.m. - 6:00 p.m. Eastern time
    Hyatt Regency Atlanta
    Centennial 1

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    This program is designed to update physicians on the latest advancements in the clinical management of beta-thalassemia, including strategies to manage transfusion dependence, transitioning care from pediatric to adult settings, and educating patients on new therapeutic options. The program will utilize prerecorded patient video clips that highlight the burden of disease, as well as the gaps in care. These conversations are designed to close gaps that currently exist within the continuum of beta-thalassemia care. This will provide real-world context to the faculty discussions and keep the patient focus top of mind. Panel discussions will challenge the faculty on their treatment decisions and provide the opportunity for the audience to reflect on best practices and their own clinical decisions.

    Chair:

    Thomas D. Coates, MD
    Children's Hospital of LA
    Los Angeles, CA

    Speakers:

    Marina Cavazzana, MD, PhD
    Smart Immune
    Paris, France

    Antonis Kattamis, MD, PhD
    'Agia Sophia' Children Hospital, First Department of Pediatrics, National and Kapodistrian University of Athens, Athens, Greece
    Athens, Greece

    Ali T. Taher, MD,PhD,FRCP
    American University of Beirut Medical Center
    Beirut, Lebanon

    Phil Talamo , Physicians' Education Resource, LLC (PER)
    Email: ptalamo@gotoper.com

    ACCESS PROGRAM HERE


    Practice Changing Evidence to Personalize Immune Thrombocytopenia Care: How the Experts Handle Cases in Today’s Environment

    This program is supported by an educational grant from Amgen, Inc.


    3:00 p.m. - 6:00 p.m. Eastern time
    VIRTUAL PROGRAM

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    This CME activity will feature expert clinician-researchers sharing information that will help clinicians be better equipped to diagnose ITP, determine which patients will benefit from a treatment, and individualize treatment for each patient while minimizing treatment-associated toxicities.

    Chair:

    Jenny M. Despotovic, DO, MS
    Texas Children's Hospital/Baylor College of Medicine
    Houston, TX

    Speaker:

    Michele P. Lambert, MD
    Children's Hosp. of Phila.
    Philadelphia, PA

    Phil Talamo , Physicians' Education Resource, LLC (PER)
    Email: ptalamo@gotoper.com

    ACCESS PROGRAM HERE


    The Evolving Landscape of Complement Inhibition Therapy: Implications for Hematology Practice

    This program is supported by Alexion Pharmaceuticals, Inc.


    3:00 p.m. - 6:00 p.m. Eastern time
    Omni Atlanta Hotel at CNN Center
    Grand Ballroom ABC, M4/Grand Ballroom Level

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    Listen to faculty discuss key components of the complement pathway, its underlying pathophysiology and how it is different in atypical haemolytic uremic syndrome (aHUS), thrombotic microangiopathy (TMA), and paroxysmal nocturnal hemoglobinuria (PNH). Experts in each disease area will then present a patient case and provide insight on the management of these patients; will review key current and emerging clinical data; will identify important patient- and disease-related factors that aid in the personalization of care; will share experiences on how to manage adverse effects; how to effectively communicate treatment considerations with patients; and the integral role of the multidisciplinary team in managing these patients. There will be an opportunity to learn more from the faculty during a live Q&A session.

    Chair:

    Spero Cataland, MD
    Ohio State University Medical Center
    Columbus, OH

    Speakers:

    Sonata Jodele, MD
    Cincinnati Children’s Hospital Medical Center
    Cincinnati, OH

    Srikanth Nagalla, MD,MS
    Miami Cancer Institute
    Miami, FL

    Kristen Holt Gresham , Medscape
    Email: kholt@webmd.net


    Thinking Outside of the Vial: Evaluating the Intricacies of Care for Patients with Iron Deficiency Anemia

    This program is supported by Pharmacosmos Therapeutics, Inc.


    3:00 p.m. - 6:00 p.m. Eastern time
    Hyatt Regency Atlanta
    International North/South

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    Iron deficiency anemia (IDA) continues to be a significant public health burden that can lead to a number of adverse health outcomes. Join our expert faculty for a satellite symposium, in coordination with the 2021 ASH Annual Meeting, as they discuss the intricacies of managing patients with iron-deficiency anemia. Take a deep dive into the practical implications of efficacy and safety data surrounding the IDA treatment landscape. Test your knowledge and skills against that of your colleagues in a quickfire polling segment. Then join the faculty for an extended Q&A session, allowing audience engagement with the entire panel. This will be a lively symposium filled with expert discussion and clinical pearls.

    Chair:

    David H. Henry, MD
    University of Pennsylvania
    Philadelphia, PA

    Speakers:

    Myles Wolf, MD, MMsc
    Duke University School of Medicine
    Durham, NC

    Michelle P. Zeller, MD
    McMaster University
    Hamilton, ON, Canada

    Jae Eising , Medscape Education
    Email: jeising@medscapelive.com


    WHAT CLINICIANS WANT TO KNOW: Addressing Current Questions and Controversies in the Management of Multiple Myeloma (Part 3 of a 4-part CME/MOC-accredited Symposia Series)

    This program is supported by Bristol-Myers Squibb Company, GlaxoSmithKline, Karyopharm Therapeutics, Oncopeptides, and Sanofi Genzyme.


    3:00 p.m. - 6:00 p.m. Eastern time
    Omni Atlanta Hotel at CNN Center
    International Ballroom E-F, M2/International Ballroom Level

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    This CME/MOC program, part 3 of a 4-part series, will focus on the management of patients with multiple myeloma. Five investigators will serve as faculty, one of whom will moderate the event. Prior to the program, Research To Practice (RTP) will recruit 5 general medical oncologists and hematologists to help frame the program’s content and agenda. RTP will work with these individuals to identify specific challenging clinical situations or questions from their practice for which they would seek input from an investigator. These clinicians will then participate in a Working Group session during which their questions will be presented. The session will be video-recorded and RTP will select excerpts for presentation during the live meeting. The symposium agenda will be divided into 5 modules, each featuring the presentation and discussion of video excerpts from the Working Group and a faculty member-led presentation formally reviewing emerging research relevant to the issues and scenarios being presented. To make the event even more relevant, attendees will participate in a survey related to the topics, questions and cases discussed. Polling results will be interspersed throughout event to foster additional debate.

    Chair:

    Robert Z. Orlowski
    The University of Texas MD Anderson Cancer Center
    Houston, TX

    Speakers:

    Larry D. Anderson Jr., MD, PhD
    UT Southwestern Medical Center
    Dallas, TX

    Morie A. Gertz, M.D.
    Mayo Clinic
    Rochester, MN

    Irene M. Ghobrial, MD
    Dana-Farber Cancer Institute
    Boston, MA

    Peter M. Voorhees, MD
    Levine Cancer Center
    Charlotte, NC

    Sylvia Eriksen , Research To Practice
    Email: meetings@researchtopractice.com


  • 4

    Evening Symposia

    7:00 p.m. - 10:00 p.m.
    Eastern time

    A Class in Session: Understanding Current and Future Therapeutic Advances Across B-Cell Lymphomas

    This program is supported by Atara Biotherapeutics, Inc., Bayer Healthcare Pharmaceuticals Inc., Beigene, Ltd., Epizyme, Genentech, Genmab US, Inc., Incyte Corporation, Karyopharm Therapeutics and Pharmacyclics LLC


    7:00 p.m. - 10:00 p.m. Eastern time
    Atlanta Marriott Marquis
    Atrium B

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    This symposium will be a one-stop opportunity to catch up on rapidly changing clinical data on recently approved and investigational agents as well as combination regimens across multiple diverse lymphomas, including FL, MZL, MCL, DLBCL, and PTLD. A panel of experts will share their approach to therapeutic decisions for patients across B-cell lymphomas considering risk stratification and the current treatment landscape, while providing a look ahead at new data and promising agents that may change practice in the near future. This symposium will include numerous patient case challenges accompanied by treatment recommendations from each expert for each case. Presentations will review available clinical trial evidence and ongoing clinical trials on novel therapeutic approaches, including targeted therapies, immune therapies (eg, antibody–drug conjugates, bispecific antibodies, immune checkpoint inhibitors, and CAR T-cell therapies), epigenetic therapies, and new combination regimens across B-cell lymphomas. Throughout the symposium, those in the audience will have chances to interact with the experts through interactive case-based challenges, polling questions, and moderated question and answer sessions that include questions sent directly to the presenters from the audience by text message.

    Chair:

    Julie M. Vose, MD, MBA
    University of Nebraska Medical Center- Fred and Pamela Buffett Cancer Center
    Omaha, NE

    Speakers:

    Brad S. Kahl, MD
    Washington University School of Medicine in St. Louis
    Saint Louis, MO

    John P. Leonard, MD
    Weill Cornell Medicine and New York Presbyterian Hospital
    New York, NY

    Clinical Care Options , Meetings Department
    Email: meetings@clinicaloptions.com


    Acquired Thrombotic Thrombocytopenic Purpura: Clinical Application of Precision Medicine and New Guidelines

    This program is supported by an educational grant from Sanofi Genzyme. Provided by Clinical Care Options, LLC.


    7:00 p.m. - 10:00 p.m. Eastern time
    Atlanta Marriott Marquis
    Atrium A

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    New science has driven innovative medical practice in the recognition and management of acquired thrombotic thrombocytopenic purpura (aTTP). This symposium will cover the continuum of care from disease diagnosis and risk stratification to practical guidance for therapeutic strategies in both initial and relapsed/refractory aTTP including new treatment options and review the latest research progress on emerging therapeutic approaches for this disease. During the symposium, program faculty will interact with the audience through the discussion of case examples and a moderated question and answer session and panel discussion. Discussion will include review of key clinical questions, available evidence, and challenges that affect therapeutic decisions as well as personal treatment recommendations from each panelist for the presented cases. Throughout the symposium, learners will be able to vote on case scenarios and text questions to the panel for their consideration. Discussion topics include:

    • Diagnosis and initial management
    • Management of relapsed/refractory disease
    • Future directions and ongoing trials

    Chair:

    Ara Metjian, MD
    University of Colorado Medicine
    Aurora, CO

    Speakers:

    Paul Coppo, MD, PhD
    Sorbonne University
    Paris, France

    Marshall Mazepa, MD
    University of Minnesota
    Minneapolis, MN

    Clinical Care Options , Meetings Department
    Email: meetings@clinicaloptions.com


    Bridging Clinical Gaps in B-Cell Lymphomas: Linking Novel Mechanisms to Advance New Treatment Strategies

    This program is supported by an educational grants from Genmab USA, Incyte Corporation, and MEI Pharma, Inc.


    7:00 p.m. - 10:00 p.m. Eastern time
    VIRTUAL PROGRAM

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    In this live virtual webcast, renowned experts will engage in case-based panel discussions about optimizing treatment strategies for patients with FL, MZL, and MCL. This lively discussion will place new developments into clinical context to help you identify patients likely to achieve greatest clinical benefit with novel therapies as well as to optimize care for patients with B-cell lymphomas.

    Chair:

    Jason R. Westin, MD
    MD Anderson
    Houston, TX

    Speakers:

    Philippe Armand, MD, PhD
    Dana Farber Cancer Institute
    Boston, MA

    Lori Leslie, MD
    Hackensack Meridian School of Medicine
    Hackensack, NJ

    Sonali M. Smith, MD
    University of Chicago
    Chicago, IL

    Pallawi Torka, MD
    Roswell Park Comprehensive Cancer Center
    Buffalo, NY

    Phil Talamo , Physicians' Education Resource, LLC
    Email: ptalamo@gotoper.com

    ACCESS PROGRAM HERE


    Caring for Patients With Hemophilia A in the Midst of a Therapeutic Revolution

    This program is supported by educational grants from Genentech, a member of the Roche Group, Sanofi Genzyme and Takeda Pharmaceuticals U.S.A., Inc.: Takeda Oncology Company. Provided by Clinical Care Options, LLC.


    7:00 p.m. - 10:00 p.m. Eastern time
    Atlanta Marriott Marquis
    Marquis Ballroom BCD

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    In this symposium, learners will be presented with an overview of current individualized therapeutic approaches for managing patients with hemophilia A and a look ahead at new data and promising agents that may soon affect practice. Renowned experts in hemophilia will discuss the evidence behind current best practices for patients with hemophilia A requiring prophylaxis, both in the presence and absence of inhibitors. The program will include interactive pertinent patient case challenges and discussions of considerations that affect therapeutic choices. Recent clinical trial data and key ongoing trials will be discussed, including emerging extended half-life clotting factors and tailoring therapy with pharmacokinetic (PK) monitoring, humanized bispecific antibody therapy, and novel therapeutic approaches with antithrombin inhibitors, anti-TFPI antibodies, and gene therapy. Learners will gain an understanding of how these agents will affect management strategies for patients with hemophilia A today and in the near future. Throughout the symposium, attendees will interact with experts through the interactive case polling questions and texting questions directly to the panel for their consideration.

    Chair:

    Miguel A. Escobar, MD
    University of Texas Health Science Center
    Houston, TX

    Speakers:

    Mark T Reding, MD
    University of Minnesota Medical Center
    Minneapolis, MN

    Guy Young, MD
    University of Southern California Keck School of Medicine
    Los Angeles, CA

    Clinical Care Options , Meetings Department
    Email: meetings@clinicaloptions.com


    Cytopenic Myelofibrosis: What Is It and How Can We Treat It?

    This program is supported by CTI BioPharma Corp.


    7:00 p.m. - 10:00 p.m. Eastern time
    Omni Atlanta Hotel at CNN Center
    Grand Ballroom ABC, M4/Grand Ballroom Level

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    Myelofibrosis (MF) is one of a group of heterogeneous hematopoietic disorders that constitute myeloproliferative neoplasms (MPNs). The severity of these disorders can range from mild to aggressive, and the diseases are associated with shortened survival and greatly compromised quality of life. Cytopenias in MF are common and often problematic and are the most common reason for interruption and/or dose reduction. Our expert panel will guide us in an interactive discussion on the unmet medical need for patients with cytopenic MF, the current treatment approaches and emerging therapies that can be used in cytopenic patients.

    Our expert panel will guide us in an interactive discussion on the unmet medical need for patients with cytopenic MF, the current treatment approaches and emerging therapies that can be used in cytopenic patients.

    Chair:

    Ruben A. Mesa, MD, FACP
    UT Health San Antonio Cancer Center
    San Antonio, TX

    Speakers:

    Raajit Rampal, MD, PhD
    Memorial Sloan Kettering Cancer Institute
    New York, NY

    Srdan Verstovsek, MD, PhD
    M.D. Anderson Cancer Center
    Houston, TX

    Kristen Holt Gresham , Medscape
    Email: kholt@webmd.net


    Healthcare Team Collaborative: Optimizing Treatment and Prevention of VTE in Patients with Hematologic Malignancies

    This program is supported by an educational grants from Bristol Myers Squibb and Pfizer Alliance.


    7:00 p.m. - 10:00 p.m. Eastern time
    VIRTUAL PROGRAM

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    The goal of this virtual satellite symposium is to review the risks for VTE in patients with cancer, review prevention strategies, analyze recent clinical trials on treatments, and discuss the contributions of the multidisciplinary team across the continuum of care.

    Chair:

    Alok A Khorana, MD
    CLEVELAND CLINIC - US
    Cleveland, OH

    Speakers:

    Dana E. Angelini, MD
    Cleveland Clinic Foundation
    Avon Lake, OH

    Marc Carrier
    University of Ottawa/The Ottawa Hospital
    Ottawa, ON, Canada

    Phil Talamo , Physicians' Education Resource, LLC (PER)
    Email: ptalamo@gotoper.com

    ACCESS PROGRAM HERE


    How We Do It™: Leveraging Novel Therapies and Patient Data to Inform Key Decisions in GvHD

    This program is supported by educational grants from CSL Behring, Incyte Corporation, Kadmon Corporation, LLC, and Syndax Pharmaceuticals, Inc.


    7:00 p.m. - 10:00 p.m. Eastern time
    Hyatt Regency Atlanta
    Centennial 2

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    This PER® How We Do It™ activity features a panel of experts who will discuss strategies for the prevention of GvHD and the latest clinical trial findings on novel therapies for patients with GvHD. Using patient case examples, these experts will present the most recent evidence for developing a comprehensive medical approach for these patients, and what this approach looks like in clinical practice.

    Chair:

    James L. Ferrara, MD, DSc
    Icahn School of Medicine at Mount Sinai
    New York, NY

    Speakers:

    Carrie Lynn Kitko, MD
    Vanderbilt University Medical Center
    Nashville, TN

    Stephanie J. Lee, MD,MPH
    Fred Hutchinson Cancer Research Center
    Seattle, WA

    Mark A. Schroeder, MD
    Washington University School of Medicine
    Saint Louis, MO

    Phil Talamo , Physicians' Education Resource, LLC (PER)
    Email: ptalamo@gotoper.com

    ACCESS PROGRAM HERE


    Leveraging Clinical Data to Inform Treatment Decisions for Patients with MDS: An Expert Case-Based Discussion

    This program is supported by an educational grants from Astex Pharmaceuticals, Inc., Bristol Myers Squibb, Geron Corporation, Gilead Sciences, Inc., and Novartis Pharmaceuticals Corporation.


    7:00 p.m. - 10:00 p.m. Eastern time
    Hyatt Regency Atlanta
    Centennial 1

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    This live, online satellite symposium is designed to provide physicians with the knowledge to best individualize care for their patients based upon disease characteristics and symptom burden. This includes analyses of recent clinical trial data to illuminate effective strategies to implement current and emerging treatment options for myeloproliferative neoplasms. Safety considerations including management of underlying and treatment-related anemia will also be addressed.

    Chair:

    Guillermo Garcia-Manero, MD
    The University of Texas MD Anderson Cancer Center
    Houston, TX

    Speakers:

    Maria Diez-Campelo, MD, PhD
    Responsable de Síndromes Mielodisplásicos Servicio de Hematología
    Salamanca, Spain

    Rami S. Komrokji, MD
    H. Lee Moffitt Cancer Center and Research Institute
    Tampa, FL

    Valeria Santini, MD
    MDS Unit, AOU Careggi, University of Florence
    Firenze, Italy

    Phil Talamo , Physicians' Education Resource, LLC (PER)
    Email: ptalamo@gotoper.com

    ACCESS PROGRAM HERE


    New Horizons in Hemophilia: Preparing for the Advent of Gene Therapy

    This program is supported by an educational grants from BioMarin Pharmaceutical Inc. and CSL Behring LLC.


    7:00 p.m. - 10:00 p.m. Eastern time
    Hyatt Regency Atlanta
    Centennial 3

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    With the growing number of treatment options for patients with hemophilia, decision-making is more complex and requires careful consideration of benefits, risks, and patient goals. Faculty will provide an overview of the role of gene therapy, recent clinical trial data, and strategies to overcome potential barriers, as well as approaches to individualize management as clinicians prepare for the arrival of gene therapy.

    Chair:

    Steven W. Pipe, MD
    University of Michigan
    Ann Arbor, MI

    Speakers:

    Stacy E. Croteau, MD
    Boston Children's Hospital
    Boston, MA

    Rebecca Krusse Jarres, MD, MPH
    University of Washington
    Seattle, 

    Andrew D Leavitt, MD
    UCSF
    San Francisco, CA

    Phil Talamo , Physicians' Education Resource, LLC (PER)
    Email: ptalamo@gotoper.com

    ACCESS PROGRAM HERE


    Overcoming Cancer-Related Anemia With Intravenous Iron: Hematologist/Oncologist Approaches For Optimizing Clinical Outcomes and Improving Patient Quality Of Life

    This program is supported by American Regent


    7:00 p.m. - 10:00 p.m. Eastern time
    Hyatt Regency Atlanta
    International North/South

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    This program is supported through an independent educational grant by American Regent.
    Activity attendees will be given the opportunity to interact with expert faculty across all clinically relevant aspects of cancer-related anemia (CRA) management, including chemotherapy-induced anemia (CIA). The session will begin with a review of iron metabolism and absorption, including the distinctions between absolute and functional iron deficiency, and the impact of those distinctions on treatment decisions. An appraisal of the etiology and foundational pathophysiology of CRA will follow, with a central emphasis on the role of hepcidin and functional iron deficiency (FID) in a hyperinflammatory disease state like cancer, and how those processes should lead to preferential use of intravenous (IV) iron versus oral iron in patients with cancer. Completed and ongoing clinical trials of IV iron for CRA will be examined, and next generation formulations with nanocolloidal drug design will be highlighted, especially their improved safety profiles. Finally, using real-world patient cases, hematology/oncology experts will share insights on how and why IV iron possesses the capacity to revolutionize treatment of CRA and CIA.

    Chair:

    George M. Rodgers, MD, PhD
    Univ. of Utah Medical Center
    Salt Lake City, UT

    Speakers:

    Michael Auerbach, MD
    Auerbach Hem-Onc Associates, Inc.
    Baltimore, MD

    Thomas G. Deloughery, MD
    Oregon Health and Science Univ.
    Portland, OR

    John Glaspy, MD, MPH
    UCLA School of Medicine
    Los Angeles, 

    Patricia A. Locantore-Ford, MD
    University of Pennsylvania, Penn Medicine
    Philadelphia, PA

    Jessica Hall , Creative Educational Concepts
    Email: jhall@ceconcepts.com


    The Tonight Show With Expert Hematologists: Let’s Talk About PNH

    This program is supported by Apellis Pharmaceuticals, Inc.


    7:00 p.m. - 10:00 p.m. Eastern time
    Omni Atlanta Hotel at CNN Center
    Grand Ballroom E, M4/Grand Ballroom Level

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    This interactive, talk show-themed, 90-minute live symposium will feature a panel of experts who will discuss key concepts and provide guidance related to the diagnosis and management of paroxysmal nocturnal hemoglobinuria (PNH). A patient video vignette will be included to showcase the patient perspective along with interactive case challenges provided by faculty to discuss the best approaches for effective treatment and management decisions. Near the conclusion of the event, expert faculty will identify key clinical pearls for PNH, followed by a robust Q&A session. Attendees will be also be able to engage in pre-/post assessment questions to test their knowledge and real-time polling during the discussions.

    Chair:

    Ilene C. Weitz
    Keck-USC School of Medicine
    Los Angeles, CA

    Speakers:

    Catherine M Broome
    MedStar Georgetown University
    Washington, DC

    Carlos M. de Castro, MD
    Duke University School of Medicine
    Durham, NC

    Kristen Holt Gresham , Medscape
    Email: kholt@webmd.net


    WHAT CLINICIANS WANT TO KNOW: Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes (Part 4 of a 4-part CME/MOC-accredited Symposia Series)

    This program is supported by an educational grants from Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Jazz Pharmaceuticals Inc and Servier Pharmaceuticals LLC


    7:00 p.m. - 10:00 p.m. Eastern time
    Omni Atlanta Hotel at CNN Center
    International Ballroom E-F, M2/International Ballroom Level

    This program has concluded. For questions, please contact the FSS managing company contact listed on hematology.org

    This CME/MOC program, part 4 of a 4-part series, will focus on the management of Acute Myeloid Leukemia and Myelodysplastic Syndromes. Five investigators will serve as faculty, one of whom will moderate the event. Prior to the program, Research To Practice (RTP) will recruit 5 general medical oncologists and hematologists to help frame the program’s content and agenda. RTP will work with these individuals to identify challenging clinical situations or questions from their practice for which they would seek input from an investigator. These clinicians will then participate in a Working Group session during which their questions will be presented. The session will be video-recorded and RTP will select excerpts for presentation during the live meeting. The symposium agenda will be divided into 5 modules, each featuring the presentation and discussion of video excerpts from the Working Group and a faculty member-led presentation formally reviewing emerging research relevant to the issues and scenarios being presented. To make the event even more relevant, attendees will participate in a survey related to the topics, questions and cases discussed. Polling results will be interspersed throughout event to foster additional debate.

    Chair:

    Harry P. Erba, MD, PhD
    University of Alabama at Birmingham
    Birmingham, AL

    Speakers:

    Alice S. Mims, MD
    The Ohio State University
    Columbus, OH

    Alexander E. Perl, MD
    University of Pennsylvania
    Philadelphia, PA

    Richard M. Stone, MD
    Dana-Farber Cancer Institute
    Boston, MA

    Geoffrey L. Uy, MD
    Washington University School of Medicine
    Saint Louis, MO

    Sylvia Eriksen , Research To Practice
    Email: meetings@researchtopractice.com